US-based Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Germnay-based Bayer AG, announced on Thursday that it has named Gustavo Pesquin as its new chief executive officer (CEO) effective 11 March 2023.
Pesquin has served as chief commercial officer at Amneal Pharmaceuticals, Inc. He has over 10 years of experience at Sanofi, where he served in leadership roles of increasing responsibility, including North America head for General Medicines and global head of the Diabetes and Cardiovascular Franchise. He has held the position of regional head, general manager, sales head and strategy head roles at Abbott and Pfizer; brand management roles at Procter & Gamble; and consultant roles with Boston Consulting Group.
Pesquin holds an MBA with a concentration in Management and Strategy, Finance and Accounting from Kellogg School of Management at Northwestern University and a bachelor's degree in Public and Business Administration from Universidad Nacional de Cuyo in Argentina.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy